PCN301 PATIENT ACCESS TO PERSONALIZED ONCOLOGY MEDICINES IN TURKEY
نویسندگان
چکیده
منابع مشابه
Access to innovative oncology medicines in Europe
This article intends to give an overview about developments in European Regulatory and Health Technology Assessment (HTA) of new cancer drugs. As background information, it will refer to an overview article by Bergmann et al. [1], which pointed out the status and the limitations of the current system. The authors discussed possible steps to improve the interface between regulators and HTA bodie...
متن کاملImpact of Introducing Costs/Qaly Threshold on Access to Oncology Medicines in Slovakia.
• Threshold: λ1 = 24-multiple and λ2 = 35-multiple of average monthly wage valid 2 years before the year of submission. • In 2014: λ1 = 19,320 €/QALY, λ2 = 28,175 €/QALY. • Drugs with ICER between λ1 and λ2 or a prevalence below 1:100,000 are reimbursed conditionally, with claw-back. • Drugs with ICER above λ2 cannot be included in the Reimbursement list and can be reimbursed only at the exempt...
متن کاملAssessing Personalized Medicines in Australia
BACKGROUND Since the mapping of the human genome in 2003, the development of biomarker targeted therapy and clinical adoption of "personalized medicine" has accelerated. Models for insurance subsidy of biomarker/test/drug packages ("codependent technologies" or technologies that work better together) are not well developed. Our aim was to create a framework to assess the safety, effectiveness, ...
متن کاملAccess to Anti-Diabetic Medicines among Patients Attending Tertiary Health Facilities in Oyo State, Nigeria
Objective: The management of Diabetes Mellitus (DM) is longterm and can be expensive. This study aimed to describe access to anti-diabetic medicines among patients in tertiary health care facilities in Oyo State, Nigeria. Materials and Methods: This was a hospital-based crosssectional study. The study sites were the University College Hospital (UCH), Ibadan, and Ladoke Akintola University Teach...
متن کاملAccess to hepatitis C medicines
Hepatitis C is a global epidemic. Worldwide, 185 million people are estimated to be infected, most of whom live in low- and middle-income countries. Recent advances in the development of antiviral drugs have produced therapies that are more effective, safer and better tolerated than existing treatments for the disease. These therapies present an opportunity to curb the epidemic, provided that t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2019
ISSN: 1098-3015
DOI: 10.1016/j.jval.2019.09.496